domingo, 17 de septiembre de 2017

APPLICATION OF GENE PROFILING IN SELECTION OF ADJUVANT THERAPY IN BREAST CANCER IN A DEVELOPING COUNTRY. - PubMed - NCBI

APPLICATION OF GENE PROFILING IN SELECTION OF ADJUVANT THERAPY IN BREAST CANCER IN A DEVELOPING COUNTRY. - PubMed - NCBI



 2017 Sep;55(3):71-72.

APPLICATION OF GENE PROFILING IN SELECTION OF ADJUVANT THERAPY IN BREAST CANCER IN A DEVELOPING COUNTRY.

Abstract

BACKGROUND:

Outcome series for genetic profile tests (MammaPrint/70GP) with medium-term follow-up are rare. We present an outcome series with 5-year follow-up from a developing country.

METHOD:

From 2006 to 2016, patients with histopathologically confirmed breast cancer (cT0-3 and cN0-1) were selected and decisions on adjuvant therapy post-surgery were based on 70GP. Data on outcomes were collected prospectively.

RESULTS:

There were 154 patients, 140 luminal type, 13 HER2 type and one triple negative; 57.8% were 70GP low-risk; only one of these did receive chemotherapy; 42.2% were high-risk; 3 patients did not receive chemotherapy. After an average follow-up of 54.1 months, only 3 systemic recurrences occurred (all skeletal metastases); all in the high-risk group that had received chemotherapy. Across both groups overall survival was 99.9% and compliance with the treatment recommendations based on 70GP was >95% in both arms. Two patients each had two tumours in the same breast with divergent 70GP results and were treated in accordance with the High-risk result. Six patients showed discordant 70GP and FISH results for HER2 where three patients did not receive Trastuzumab on basis of 70GP, none of these tumours recurred. A further 11 patients had equivocal immunohistochemistry and a FISH was not done, therapy was decided upon considering the 70GP result and none of these patients had any recurrences.

CONCLUSION:

Chemotherapy use was much reduced versus the rate of use with conventional methods using 70GP and it may possibly be reasonable to replace immunohistochemistry for ER, PR and HER2 with 70GP especially considering borderline expression.

PMID:
 
28876582

No hay comentarios:

Publicar un comentario